Observational Study for Patients Receiving a Kidney Transplant After Vonsetamig Treatment
This study is for adults aged 18 to 70 who previously participated in the R5459-RT-1944 study and received at least one dose of vonsetamig, and then had a kidney transplant. The main goal is to continue observing how vonsetamig affects the body and to track your health outcomes after your kidney transplant. No new medication will be given during this study. Researchers will be looking at any side effects (adverse events) you experience for up to 12 months after your kidney transplant. The study plans to include 20 participants, but its current recruitment status is unclear.
- Study design
- This is an observational study, meaning no new treatment will be given. It plans to enroll 20 participants.
- What's involved
- You would need to be willing and able to attend clinic visits and follow study-related procedures. These observations will continue for up to 12 months after your kidney transplant.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for up to 12 months after their kidney transplant to monitor adverse events.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive a Kidney Transplant
At a glance
Conditions
Where it's being run
9 sites across 7 statesStudy leadership
- Clinical Trial Management · STUDY_DIRECTOR · Regeneron Pharmaceuticals
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Incidence of Adverse EventsUp to 12 months post-kidney transplant
- Incidence of Serious Adverse EventsUp to 12 months post-kidney transplant